Processing...
Clinical Trials for Breast Cancer
Search
Search
There are 321 active trials for advanced/metastatic breast cancer.
Click on a trial to see more information.
321 trials meet filter criteria.
Sort by:
TrialFetch AI summary: This trial is enrolling adults with previously treated, locally advanced or metastatic solid tumors (including urothelial carcinoma and other Nectin-4–positive types) who have measurable disease and good performance status. Patients receive [225Ac]Ac-AKY-1189, an investigational Nectin-4–targeting radiopharmaceutical that delivers actinium-225 directly to tumor cells, in up to six cycles following Nectin-4 PET imaging confirmation.
ClinicalTrials.gov ID: NCT07020117
TrialFetch AI summary: Eligible patients are adults with advanced, unresectable, or recurrent solid tumors or lymphomas that have progressed on standard therapy and have at least one injectable, measurable lesion; they will receive intratumoral ONM-501, a dual-activating STING agonist, either alone or in combination with intravenous cemiplimab, a PD-1 inhibitor. Key exclusions include active or untreated brain metastases, recent major surgery, and active autoimmune disease (for combination cohorts).
ClinicalTrials.gov ID: NCT06022029
TrialFetch AI summary: This trial enrolls adults with newly diagnosed, untreated metastatic triple negative breast cancer that is negative for PD-L1, evaluating nab-paclitaxel plus durvalumab (PD-L1 inhibitor) and tremelimumab (CTLA-4 inhibitor), with or without the addition of a personalized neoantigen peptide vaccine plus poly-ICLC as an immunologic adjuvant. Patients must have accessible tumor tissue, good performance status, and meet organ function requirements.
ClinicalTrials.gov ID: NCT03606967
TrialFetch AI summary: This trial enrolls adults with advanced solid tumors, particularly breast cancer (including HR+/HER2-, HER2+, and HER2-low subtypes), or select non-breast cancers, all of which harbor a PI3KαH1047R mutation; participants receive OKI-219, a highly selective PI3KαH1047R inhibitor, as monotherapy or in combination with fulvestrant or trastuzumab. Eligible patients must have measurable disease, ECOG 0-1, and adequate organ function.
ClinicalTrials.gov ID: NCT06239467
TrialFetch AI summary: This trial enrolls adults with ER-positive, HER2-negative advanced or metastatic breast cancer previously treated with endocrine therapy (and CDK4/6 inhibitors depending on arm) to evaluate the safety and efficacy of elacestrant, an oral selective estrogen receptor degrader, in combination with various targeted agents including alpelisib (PI3K inhibitor), everolimus (mTOR inhibitor), palbociclib/abemaciclib/ribociclib (CDK4/6 inhibitors), and capivasertib (AKT inhibitor). Key exclusions are active CNS disease, symptomatic visceral crisis, and prior use of elacestrant or the relevant combination partner in the metastatic setting.
ClinicalTrials.gov ID: NCT05563220
TrialFetch AI summary: This trial enrolls adults with advanced solid tumors harboring deleterious or suspected deleterious BRCA1/2 or other homologous recombination repair mutations—such as HER2-negative BRCA-mutant breast cancer, high-grade serous ovarian or fallopian tube cancer, metastatic castration-resistant prostate cancer, and pancreatic cancer—who have progressed on, are intolerant to, or are ineligible for standard therapies (including PARP inhibitors). Patients receive the investigational oral USP1 inhibitor XL309, which disrupts DNA repair, as monotherapy or in combination with olaparib.
ClinicalTrials.gov ID: NCT05932862
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic hepatocellular, renal cell, breast, ovarian/fallopian, or endometrial/primary peritoneal cancers involving the abdomen or thorax who have progressed on or are intolerant to standard therapies, and evaluates safety of Tumor Treating Fields (TTF) in combination with either cabozantinib (a multi-kinase inhibitor targeting MET, VEGFR, and AXL) or nab-paclitaxel plus atezolizumab (a PD-L1 inhibitor).
ClinicalTrials.gov ID: NCT05092373
TrialFetch AI summary: This trial enrolls adults with advanced, nonresectable, or metastatic solid tumors—including HR+/HER2- breast cancer, platinum-resistant serous ovarian, endometrial, and other tumors with likely CDK2 dependency—who have progressed on standard therapies. Patients receive the investigational selective CDK2 inhibitor BG-68501 as monotherapy or in combination with fulvestrant, with HR+/HER2- breast cancer patients also eligible for a triple combination with fulvestrant and the selective CDK4 inhibitor BGB-43395.
ClinicalTrials.gov ID: NCT06257264
TrialFetch AI summary: Eligible patients are adults with advanced or metastatic triple-negative breast cancer, high-grade serous ovarian, primary peritoneal, fallopian-tube, or serous endometrial cancer, all with TP53 mutation/loss and progression after at least one prior line of therapy. Participants receive AO-252, an investigational oral small-molecule inhibitor of TACC3 protein-protein interactions.
ClinicalTrials.gov ID: NCT06136884
TrialFetch AI summary: This trial enrolls adults with ER-positive, HER2-negative, GRPR-positive advanced breast cancer who have relapsed early after (neo)adjuvant endocrine therapy or progressed on prior endocrine therapy plus a CDK4/6 inhibitor, with up to one prior line of advanced therapy and no prior fulvestrant. Patients receive [177Lu]Lu-NeoB, a GRPR-targeted radioligand delivering beta radiation, in combination with ribociclib and fulvestrant.
ClinicalTrials.gov ID: NCT05870579